Acne, hidradenitis suppurativa, and psoriasis are all influenced by obesity and metabolic and dietary factors. Clinical management should ideally include a dermatologist, endocrinologist, and nutritionist.
Adding obicetrapib to existing lipid-lowering therapy reduces LDL cholesterol levels by 30% in patients with atherosclerotic CV disease or heterozygous familial hypercholesterolemia.
Is amylin the missing piece of the puzzle when it comes to precision diabetology? Explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to clinical significance.
Long-term SGLT2 inhibitor use is associated with an increased risk for postoperative euglycemic ketoacidosis but lower risks for postoperative acute kidney injury and mortality.
Understand the pathogenic mechanisms underlying diabetic foot development in patients with rheumatic diseases, the impact of chronic inflammation and drug therapy, and current diagnostic approaches, treatment strategies, and preventive measures.
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
A 64-year-old man with type 1 diabetes presented with notable abdominal swelling over the previous 3 months. Investigations led to a diagnosis of pseudoascites and celiac disease was identified as the cause.
Cutaneous lymphoma should be considered in patients with long-standing, poorly controlled type 2 diabetes and chronic non-healing skin lesions. In this case, primary cutaneous B-cell lymphoma was misdiagnosed as a skin infection.
Although it seems to be a rare complication, there should be a high index of suspicion for colonic ischemia in patients taking a GLP-1 receptor agonist who present with abdominal pain.
Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.
Diabetic foot ulcers (DFUs) are a devastating complication of diabetes mellitus (DM) that affect millions of people worldwide every year. They have a long-term impact on patients' quality of life and pose a significant challenge for both patients …
Despite all the advances in ophthalmic care, several of these surface disorders are challenging and may present with significant visual impairments that complicate their management. The spectrum may involve persistent epithelial defects (PEDs) …
India has emerged as one of the largest global markets for antidiabetic medications, with over 100 million individuals living with diabetes [ 1 , 2 ]. As the prevalence of chronic diseases continues to rise, the use of fixed-dose combinations …
Diabetes mellitus (DM) is a chronic d isease that occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces [ 1 ], and is associated with many ocular complications, such as cataract [ …
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
Treating children with hormone disorders is complex and requires tailored management. To help you provide the most effective care, we deliver resources covering adrenal, thyroid, pituitary, growth, and puberty disorders, obesity, and diabetes.
Type 2 diabetes mellitus (T2DM) is an escalating global health concern, with its prevalence largely driven by the concurrent rise in obesity [ 1 , 2 ]. As reported by the International Diabetes Federation, diabetes affected approximately 463 …
The association between type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is increasing in clinical practice, especially in Western countries. Both …
Patients with pulmonary arterial hypertension (PAH) in clinical practice often present with risk factors associated with cardiovascular diseases [ 1 – 7 ], defined in the 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) …
Guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend a holistic person-centred approach to type 2 diabetes (T2D) management, with goals of care being to prevent …
Acne, hidradenitis suppurativa, and psoriasis are all influenced by obesity and metabolic and dietary factors. Clinical management should ideally include a dermatologist, endocrinologist, and nutritionist.
Is amylin the missing piece of the puzzle when it comes to precision diabetology? Explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to clinical significance.
Understand the pathogenic mechanisms underlying diabetic foot development in patients with rheumatic diseases, the impact of chronic inflammation and drug therapy, and current diagnostic approaches, treatment strategies, and preventive measures.
A thorough overview of the safety and efficacy of once-weekly basal insulin icodec in type 1 and 2 diabetes, covering pharmacology, pharmacokinetics, adverse effects, drug interactions, and dose recommendations.
